BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33287744)

  • 1. TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.
    Naeser Y; Helgadottir H; Brandberg Y; Hansson J; Bagge RO; Elander NO; Ingvar C; Isaksson K; Flygare P; Nilsson C; Jakobsson F; Del Val Munoz O; Valachis A; Jansson M; Sparring C; Ohlsson L; Dyrke U; Papantoniou D; Sundin A; Ullenhag GJ
    BMC Cancer; 2020 Dec; 20(1):1197. PubMed ID: 33287744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma.
    Podlipnik S; Moreno-Ramírez D; Carrera C; Barreiro A; Manubens E; Ferrandiz-Pulido L; Sánchez M; Vidal-Sicart S; Malvehy J; Puig S
    Br J Dermatol; 2019 May; 180(5):1190-1197. PubMed ID: 29876940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
    Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
    J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.
    Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
    Eur J Cancer; 2013 Aug; 49(12):2705-16. PubMed ID: 23583439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
    De Smedt J; Van Kelst S; Boecxstaens V; Stas M; Bogaerts K; Vanderschueren D; Aura C; Vandenberghe K; Lambrechts D; Wolter P; Bechter O; Nikkels A; Strobbe T; Emri G; Marasigan V; Garmyn M
    BMC Cancer; 2017 Aug; 17(1):562. PubMed ID: 28835228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial.
    Stoffels I; Herrmann K; Rekowski J; Jansen P; Schadendorf D; Stang A; Klode J
    Trials; 2019 Feb; 20(1):99. PubMed ID: 30717811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of Life in the First Year of Follow-Up in a Randomized Multicenter Trial Assessing the Role of Imaging after Radical Surgery of Stage IIB-C and III Cutaneous Melanoma (TRIM Study).
    Naeser Y; Helgadottir H; Hansson J; Ingvar C; Elander NO; Flygare P; Nilsson C; Jakobsson F; Valachis A; Papantoniou D; Nordin Danfors A; Johansson H; Sundin A; Brandberg Y; Ullenhag GJ
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
    Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
    J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
    Simberg-Danell C; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
    Int J Cancer; 2016 Aug; 139(3):543-53. PubMed ID: 27004457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.
    Macfarlane DJ; Sondak V; Johnson T; Wahl RL
    J Clin Oncol; 1998 May; 16(5):1770-6. PubMed ID: 9586890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage-specific direct health care costs in patients with cutaneous malignant melanoma.
    Lyth J; Carstensen J; Synnerstad I; Lindholm C
    J Eur Acad Dermatol Venereol; 2016 May; 30(5):789-93. PubMed ID: 25807966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
    Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
    J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review.
    Krug B; Crott R; Lonneux M; Baurain JF; Pirson AS; Vander Borght T
    Radiology; 2008 Dec; 249(3):836-44. PubMed ID: 19011184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of malignant melanoma in central Europe: risk factors and prognostic predictors. Results of the Central Malignant Melanoma Registry of the German Dermatological Society.
    Garbe C; Orfanos CE
    Pigment Cell Res; 1992; Suppl 2():285-94. PubMed ID: 1409431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.
    Seegenschmiedt MH; Keilholz L; Altendorf-Hofmann A; Urban A; Schell H; Hohenberger W; Sauer R
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):607-18. PubMed ID: 10348291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430.
    Sosman JA; Moon J; Tuthill RJ; Warneke JA; Vetto JT; Redman BG; Liu PY; Unger JM; Flaherty LE; Sondak VK
    Cancer; 2011 Oct; 117(20):4740-06. PubMed ID: 21455999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.